Recent advancements in tissue engineering for stem cell-based cardiac therapies

Therapeutic Delivery

Volumn 4, Issue 4, 2013, Pages 503-516

  Le Huu, Alice ^a   Paul, Arghya ^b   Xu, Liqin ^c   Prakash, Satya ^b   Shum Tim, Dominique ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DACRON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MICROSPHERE; MOLECULAR SCAFFOLD;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPLASTY; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; DISEASE CONTROL; DYSLIPIDEMIA; ELECTROSPINNING; ELECTROSPRAY; FIBRINOLYTIC THERAPY; HEART; HEART GRAFT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYDROGEL; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR ASSIST DEVICE; LIFESTYLE MODIFICATION; MICROENCAPSULATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR;

EID: 84875949550     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.13     Document Type: Review

References (147)

1. Kolansky DM. Acute coronary syndromes. Morbidity, mortality, and pharmacoeconomic burden. Am. J. Manag. Care 15, S36-S41 (2009
2. Atanasijevic-Kunc M, Drinovec J, Rucigaj S, Mrhar A. Simulation analysis of coronary heart disease, congestive heart failure and end-stage renal disease economic burden. Math. Comput. Simul. 82(3), 494-507 (2011
3. D'agostino R, Vasan R, Zachariah J. The burden of increasing worldwide cardiovascular disease. In: Hurst's The Heart Uster V, Walsh R, Harrington R (Eds). McGraw-Hill, NY, USA (2011
4. Visser CA. Left ventricular remodeling after myocardial infarction: Importance of residual myocardial viability and ischemia. Heart 89(10), 1121 (2003
5. Rogers WJ. Contemporary management of acute myocardial infarction. Am. J. Med. 99(2), 195 (1995
6. Lilly L. Pathophysiology of Heart Disease (3rd Edition). Lilly LS (Ed.). Lippincott Williams and Wilkins, MD, USA 157 (2003
7. Nadal-Ginard B, Kajstura J, Anversa P, Leri A. A matter of life and death: Cardiac myocyte apoptosis and regeneration. J. Clin. Invest. 111(10), 1457-1459 (2003
8. Clerk A, Cole SM, Cullingford TE, Harrison JG, Jormakka M, Valks DM. Regulation of cardiac myocyte cell death. Pharmacol. Ther. 97(3), 223 (2003
9. Ren G, Dewald O, Frangogiannis NG. Inflammatory mechanisms in myocardial infarction. Curr. Drug Targets Inflamm. Allergy 2(3), 242-256 (2003
10. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53(1), 31-47 (2002
11. Trescher K, Bernecker O, Fellner B et al. Inflammation and postinfarct remodeling: Overexpression of IkB prevents ventricular dilation via increasing TIMP levels. Cardiovasc. Res. 69(3), 746-754 (2006
12. Cohn JN. Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation 91(10), 2504-2507 (1995
13. Hori M, Nishida K. Oxidative stress and left ventricular remodeling after myocardial infarction. Cardiovasc. Res. 81(3), 457-464 (2009
14. Huxley RR, Barzi F, Lam TH et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease/clinical perspective. Circulation 124(19), 2056-2064 (2011
15. Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk: Observations and predictions among middle-aged population in eastern Finland. Circulation 97(11), 1087-1094 (1998
16. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: A Canadian coronary atherosclerosis intervention trial (CCAIT) substudy. Circulation 92(9), 2404-2410 (1995
17. Weintraub WS, Pederson TR. Atherosclerosis and restenosis: Reflections on the lovastatin restenosis trial and Scandinavian. Am. J. Cardiol. 78(9), 1036 (1996
18. Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circuluation 112(15), 2354-2363 (2005
19. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 121(6), 750-758 (2010
20. Miller CD, Banerjee A, Mahaffey KW et al. Treatment and outcomes of patients with evolving myocardial infarction: Experiences from the SYNERGY trial. Eur. Heart J. 28(9), 1079-1084 (2007
21. Phillips SJ, Kongtahworn C, Skinner JR, Zeff RH. Emergency coronary artery reperfusion: A choice therapy for evolving myocardial infarction. Results in 339 patients. J. Thorac. Cardiovasc. Surg. 56(5), 679-688 (1983
22. White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation 97(16), 1632-1646 (1998
23. Keeley EC, Grines CL. Primary coronary intervention for acute myocardial infarction. JAMA 291(6), 736-739 (2004
24. Bocchi EA, Guimarães G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. Circulation 106(9), 1097-1103 (2002
25. Moazemi K, Chana JS, Willard AM, Kocheril AG. Intravenous vasodilator therapy in congestive heart failure. Drugs Aging 20(7), 485-508 (2003
26. Simpson D, Noble S, Goa KL. Perindopril: In congestive heart failure. Drugs 62(9), 1367-1377 (2002
27. Blanc JJ, Bertault-Valls V, Fatemi M, Gilard M, Pennec PY, Etienne Y. Midterm benefits of left univentricular pacing in patients with congestive heart failure. Circulation 109(14), 1741-1744 (2004
28. Mcmurray J, Pfeffer M. Heart failure. Lancet 365, 1877-1889 (2005
29. Birks EJ, George RS, Hedger M et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy/clinical perspective. Circulation 123(4), 381-390 (2011
30. Pal JD, Klodell CT, John R et al. Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation 120(11 Suppl. 1), S215-S219 (2009
31. Wang F, Guan J. Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy. Adv. Drug Deliv. Rev. 62(7-8), 784-797 (2010
32. Forte E, Chimenti I, Barile L et al. Cardiac cell therapy: The next (re)generation. Stem Cell Rev. 7(4), 1018-1030 (2011
33. Perin E. Stem cell therapy for cardiovascular disease. Tex. Heart Inst. J. 33(2), 204-208 (2006
34. Perin EC, Silva GV. Cell-based therapy for chronic ischemic heart disease-a clinical perspective. Cardiovasc. Ther. 29(3), 211-217 (2011
35. Wang JS, Shum-Tim D, Chedrawy E, Eliopoulis N, Galipeau J, Chiu RJ. Marrow stromal cells for cellular cardiomyoplasty: The importance of microenvironment for milieu dependent differentiation (Abstract). Circulation 102(18), II-683 (2000
36. Koh GY, Soonpaa MH, Klug MG, Field LJ. Long-term survival of AT-1 cardiomyocyte grafts in syngeneic myocardium. Am. J. Physiol. Heart Circ. Physiol. 264(5), H1727-H1733 (1993
37. Li RK, Jia ZQ, Weisel RD, Merante F, Mickle DA. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J. Mol. Cell. Cardiol. 31(3), 513-522 (1999
38. Robinson S, Cho P, Levitsky H et al. Arterial delivery of genetically labeled skeletal myoblasts to the murine heart: Long-term survival and phenotypic modification of implanted myoblasts. Cell Transpl. 5, 77-91 (1996
39. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J. Clin. Invest. 98(11), 2512-2523 (1996
40. Hutcheson K, Atkins B, Hueman M, Hopkins M, Glower D, Taylor D. Comparing the benefits of cellular cardiomyoplasty with skeletal myoblasts or dermal fibroblasts on myocardial performance. Cell Transpl. 9, 259-269 (2000
41. Li R, Weisel R, Mickle D, Choi A, Yau T. Survival and function of bioengineered cardiac grafts. Circulation 100(19 Suppl. 2), 163-169 (1999
42. Taylor D, Atkins B, Hungspreugs P et al. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nat. Med. 4(10), 929-933 (1998
43. Atkins BZ, Hueman MT, Meuchel JM, Cottman MJ, Hutcheson KA, Taylor DA. Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium. J. Heart Lung Transplant. 18(12), 1173-1180 (1999
44. Chiu RJ, Zibaitis A, Kao R. Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg. 60, 12-18 (1995
45. Jain M, Dersimonian H, Brenner DA et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 103(14), 1920-1927 (2001
46. Gmeiner M, Zimpfer D, Holfeld J et al. Improvement of cardiac function in the failing rat heart after transfer of skeletal myoblasts engineered to overexpress placental growth factor. J. Thorac. Cardiovasc. Surg. 141(5), 1238-1245 (2011
47. Khan M, Kutala VK, Vikram DS et al. Skeletal myoblasts transplanted in the ischemic myocardium enhance in situ oxygenation and recovery of contractile function. Am. J. Physiol. Heart Circ. Physiol. 293(4), H2129-H2139 (2007
48. Povsic TJ, O'connor CM, Henry T et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am. Heart J. 162(4), 654-662 (2011
49. Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. Am. Hear J. 148(3), 531-537 (2004
50. Pagani FD, Dersimonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans: histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol. 41(5), 879-888 (2003
51. Fernandes S, Amirault JC, Lande G et al. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovasc. Res. 69(2), 348-358 (2006
52. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7(4), 430-436 (2001
53. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81(4), 1161-1172 (1990
54. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 410(6829), 701-705 (2001
55. Schuster MD, Kocher AA, Seki T et al. Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am. J. Physiol. Heart Circ. Physiol. 287(2), H525-H532 (2004
56. Hirsch A, Nijveldt R, Van Der Vleuten PA et al. Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: Rationale and design of the HEBE trial - A prospective, multicenter, randomized trial. Am. Heart J. 152(3), 434- 441 (2006
57. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomized controlled trial. Lancet 367(9505), 113-121 (2006
58. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Eng. J. Med. 355(12), 1199- 1209 (2006
59. Schächinger V, Erbs S, Elsässer A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Eng. J. Med. 355(12), 1210-1221 (2006
60. Wollert K, Meyer G, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomized controlled clinical trial. Lancet 364(9429), 141-148 (2004
61. Jeevanantham V, Butler M, Saad A, Abdel- Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: A systematic review and meta-analysis. Circulation 126(5), 551-568 (2012
62. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: A paradigm shift in human myocardial biology. Circ. Res. 109(8), 941-961 (2011
63. Anversa P, Leri A, Kajstura J. Cardiac regeneration. J. Am. Coll. Cardiol. 47(9), 1769-1776 (2006
64. Bearzi C, Rota M, Hosoda T et al. Human cardiac stem cells. Proc. Natl Acad. Sci. USA 104(35), 14068-14073 (2007
65. Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95(9), 911-921 (2004
66. Torella D, Ellison G, Méndez-Ferrer S, Ibanez B, Nadal-Ginard B. Resident human cardiac stem cells: Role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med. 3(1), S8-S13 (2006
67. Urbanek K, Quaini F, Tasca G et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100(18), 10440-10445 (2003
68. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomized Phase I trial. Lancet 379(9819), 895-904 (2012
69. Bolli R, Chugh AR, D'Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomized Phase I trial. Lancet 378(9806), 1847-1857 (2011
70. Strauer BE. Myocardial oxygen consumption in chronic heart disease: Role of wall stress, hypertrophy and coronary reserve. Am. J. Cardiol. 44(4), 730-740 (1979
71. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart from the methodological origin to clinical practice. J. Am. Coll. Cardiol. 58(11), 1095-1104 (2011
72. Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361(9351), 45-46 (2003
73. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 103(11), 1204-1219 (2008
74. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J. Clin. Invest. 115(3), 572-583 (2005
75. Nygren J, Jovinge S, Breitbach M et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10(5), 494-501 (2004
76. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann. NY. Acad. Sci. 938(1), 221-230 (2001
77. Noiseux N, Gnecchi M, Lopez-Ilasaca M et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther. 14(6), 840-850 (2006
78. Giordano FJ, Gerber HP, Williams SP et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl Acad. Sci. USA 98(10), 5780-5785 (2001
79. Kitta K, Day RM, Kim Y, Torregroza I, Evans T, Suzuki YJ. Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells. J. Biol. Chem. 278(7), 4705-4712 (2003
80. Chen G, Nayan M, Duong M et al. Marrow stromal cells for cell-based therapy: The role of antiinflammatory cytokines in cellular cardiomyoplasty. Ann. Thorac. Surg. 90(1), 190-197 (2010
81. Taylor D. Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure. Curr. Control. Trials Cardiovasc. Med. 2(5), 208-210 (2001
82. Stolzing A, Scutt A. Age-related impairment of mesenchymal progenitor cell function. Aging Cell 5(3), 213-224 (2006
83. Nayan M, Paul A, Chen G, Chiu RCJ, Prakash S, Shum-Tim D. Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction: In vitro and in vivo investigation. J. Tissue Eng. 2(1), (2011
84. Wolf D, Reinhard A, Seckinger A, Katus H, Kuecherer H, Hansen A. Dose-dependent effects of intravenous allogeneic mesenchymal stem cells in the infarcted porcine heart. Stem Cells Dev. 18(2), 321-329 (2009
85. Psaltis PJ, Carbone A, Nelson AJ et al. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc. Interv. 3(9), 974-983 (2010
86. Quevedo HC, Hatzistergos KE, Oskouei BN et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl Acad. Sci. USA 106(33), 14022-14027 (2009
87. Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54(24), 2277-2286 (2009
88. Dib N, Henry T, Demaria A et al. The first US study to assess the feasibility and safety of endocardial delivery of allogenic mesenchymal precursor cells in patient with heart failure: Three-month interim analysis. Circulation 120, S810 (2009
89. Perin EC. A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic and nonischemic heart failure. Presented at: American Heart Association Scientific Session, Orlando, FL, USA, 14 November 2011.
90. Huang XP, Sun Z, Miyagi Y et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair/clinical perspective. Circulation 122(23), 2419-2429 (2010
91. De Ugarte D, Morizono K, Elbarbary A et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174, 101-109 (2003
92. Paul A, Srivastava S, Chen G, Shum-Tim D, Prakash S. Functional assessment of adipose stem cells for xenotransplantation using myocardial infarction immunocompetent models: Comparison with bone marrow stem cells. Cell Biochem. Biophys. doi:10.1007/ s12013-011-9323-0 (2011) (Epub
93. Suzuki K, Murtuza B, Beauchamp JR et al. Role of interleukin-1b in acute inflammation and graft death after cell transplantation to the heart. Circulation 110(11 Suppl. 1), II219-II224 (2004
94. Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, Marbán E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ. Res. 106(10), 1570-1581 (2010
95. Müller-Ehmsen J, Whittaker P, Kloner RA et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J. Mol. Cell. Cardiol. 34(2), 107-116 (2002
96. Retuerto MA, Schalch P, Patejunas G et al. Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J. Thorac. Cardiovasc. Surg. 127(4), 1041-1050 (2004
97. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J. Mol. Cell. Cardiol. 33(5), 907-921 (2001
98. Teng CJ, Luo J, Chiu RCJ, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: Implications for cellular cardiomyoplasty. J. Thorac. Cardiovasc. Surg. 132(3), 628-632 (2006
99. Singelyn JM, Dequach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials 30(29), 5409-5416 (2009
100. Singelyn JM, Christman KL. Modulation of material properties of a decellularized myocardial matrix scaffold. Macromol. Biosci. 11(6), 731-738 (2011
101. Christensen L, Dionne K, Lysaght M. Biomedical Application of Immobilized Cells. CRC Press, Boca Raton, FL, USA. (1993
102. Al-Kindi A, Chen G, Asenjo J. Microencapsulation to reduce mechanical loss of microspheres: Implication in myocardial cell therapy. Presented at: Canadian Cardiovascular Congress. Quebec, Canada, 20-24 October 2007.
103. Al Kindi AH, Asenjo JF, Ge Y et al. Microencapsulation to reduce mechanical loss of microspheres: Implications in myocardial cell therapy. Eur. J. Cardiothorac. Surg. 39(2), 241-247 (2011
104. Trouche E, Girod Fullana S, Mias C et al. Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ. Cell Transplant. 19(12), 1623-1633 (2010
105. Chen H, Ouyang W, Jones M et al. Preparation and characterization of novel polymeric microcapsules for live cell encapsulation and therapy. Cell Biochem. Biophys. 47(1), 159-167 (2007
106. Orive G, Maria Hernández R, Rodríguez Gascón A et al. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol. 22(2), 87-92 (2004
107. Paul A, Cantor A, Shum-Tim D, Prakash S. Superior cell delivery features of genipin crosslinked polymeric microcapsules: Preparation, in vitro characterization and pro-angiogenic applications using human adipose stem cells. Mol. Biotechnol. 48(2), 116-127 (2011
108. Berthiaume F, Moghe PV, Toner M, Yarmush ML. Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration. FASEB J. 10(13), 1471-1484 (1996
109. Prakash S, Khan A, Paul A. Nanoscaffold based stem cell regeneration therapy: Recent advancement and future potential. Expert Opin. Biol. Ther. 10(12), 1649-1661 (2010
110. Townsend-Nicholson A, Jayasinghe SN. Cell electrospinning: A unique biotechnique for encapsulating living organisms for generating active biological microthreads/scaffolds. Biomacromolecules 7(12), 3364-3369 (2006
111. Mironov V, Kasyanov V, Markwald RR. Nanotechnology in vascular tissue engineering: From nanoscaffolding towards rapid vessel biofabrication. Trends Biotechnol. 26(6), 338-344 (2008
112. Lin HH, Cheng YL. In situ thermoreversible gelation of block and star copolymers of poly(ethylene glycol) and poly(N-isopropylacrylamide) of varying architectures. Macromolecules 34(11), 3710-3715 (2001
113. Ren K, Wang Y, Ji J, Lin Q, Shen J. Construction and deconstruction of PLL/ DNA multilayered films for DNA delivery: Effect of ionic strength. Colloids Surf. B Biointerfaces 46(2), 63-69 (2005
114. Smith IO, Liu XH, Smith LA, Ma PX. Nanostructured polymer scaffolds for tissue engineering and regenerative medicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(2), 226-236 (2009
115. Webber MJ, Tongers J, Renault MA, Roncalli JG, Losordo DW, Stupp SI. Development of bioactive peptide amphiphiles for therapeutic cell delivery. Acta Biomaterialia 6(1), 3-11 (2010
116. Beniash E, Hartgerink JD, Storrie H, Stendahl JC, Stupp SI. Self-assembling peptide amphiphile nanofiber matrices for cell entrapment. Acta Biomaterialia 1(4), 387-397 (2005
117. Smith LA, Liu X, Ma PX. Tissue engineering with nano-fibrous scaffolds. Soft Matter 4(11), 2144-2149 (2008
118. Guan J, Fujimoto KL, Sacks MS, Wagner WR. Preparation and characterization of highly porous, biodegradable polyurethane scaffolds for soft tissue applications. Biomaterials 26(18), 3961-3971 (2005
119. Zimmermann WH, Schneiderbanger K, Schubert P et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 90(2), 223-230 (2002
120. Thompson CA, Nasseri BA, Makower J et al. Percutaneous transvenous cellular cardiomyoplasty: A novel nonsurgical approach for myocardial cell transplantation. J. Am. Coll. Cardiol. 41(11), 1964-1971 (2003
121. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J. Am. Coll. Cardiol. 44(3), 654-660 (2004
122. Ozawa T, Mickle DA, Weisel RD, Koyama N, Ozawa S, Li RK. Optimal biomaterial for creation of autologous cardiac grafts. Circulation 106(12 Suppl. 1), i176-i182 (2002
123. Leor J, Aboulafia-Etzion S, Dar A et al. Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium? Circulation 102(Suppl. 3), III56-III61 (2000
124. Zhang P, Zhang H, Wang H, Wei Y, Hu S. Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif. Organs 30(2), 86-93 (2006
125. Huang NF, Lam A, Fang Q, Sievers RE, Li S, Lee RJ. Bone marrow-derived mesenchymal stem cells in fibrin augment angiogenesis in the chronically infarcted myocardium. Regen. Med. 4(4), 527-538 (2009
126. Simpson D, Liu H, Fan T-HM, Nerem R, Dudley SC. A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. Stem Cells 25(9), 2350-2357 (2007
127. Proulx MK, Carey SP, Ditroia LM et al. Fibrin microthreads support mesenchymal stem cell growth while maintaining differentiation potential. J. Biomed. Mater. Res. A 96A(2), 301-312 (2011
128. Hodde J. Naturally occurring scaffolds for soft tissue repair and regeneration. Tissue Eng. 8(2), 295-308 (2002
129. Badylak S, Obermiller J, Geddes L, Matheny R. Extracellular matrix for myocardial repair. Heart Surg. Forum 6(2), E20-E26 (2003
130. Voytik-Harbin SL, Brightman AO, Kraine MR, Waisner B, Badylak SF. Identification of extractable growth factors from small intestinal submucosa. J. Cell. Biochem. 67(4), 478-491 (1997
131. Kochupura PV, Azeloglu EU, Kelly DJ et al. Tissue-engineered myocardial patch derived from extracellular matrix provides regional mechanical function. Circulation 112(9 Suppl), i144-i149 (2005
132. Wei HJ, Chen CH, Lee WY et al. Bioengineered cardiac patch constructed from multilayered mesenchymal stem cells for myocardial repair. Biomaterials 29(26), 3547-3556 (2008
133. Ota T, Gilbert TW, Badylak SF, Schwartzman D, Zenati MA. Electromechanical characterization of a tissue-engineered myocardial patch derived from extracellular matrix. J. Thorac. Cardiovasc. Surg. 133(4), 979-985 (2007
134. Dvir T, Timko BP, Brigham MD et al. Nanowired three-dimensional cardiac patches. Nat. Nano 6(11), 720-725 (2011
135. Andreu N, Thomas D, Saraiva L et al. In vitro and in vivo interrogation of bio-sprayed cells. Small 8(16), 2495-2500 (2012
136. Jayasinghe SN, Qureshi AN, Eagles Pa. Electrohydrodynamic jet processing: An advanced electric-field-driven jetting phenomenon for processing living cells. Small 2(2), 216-219 (2006
137. Eagles P, Qureshi A, Jayasinghe S. Electrohydrodynamic jetting of mouse neuronal cells. Biochem. J. 1(394), 375-378 (2006
138. Ward E, Chan E, Gustafsson K, Jayasinghe SN. Combining bio-electrospraying with gene therapy: A novel biotechnique for the delivery of genetic material via living cells. Analyst 135(5), 1042-1049 (2010
139. Barry SP, Jayasinghe SN, Pericleous C, Hubank M, Latchman DS, Stephanou A. Gene expression studies on bio-electrosprayed primary cardiac myocytes. Biotechnol. J. 3(4), 530-535 (2008
140. Jayasinghe SN, Warnes G, Scotton CJ. Bio-electrosprayed living composite matrix implanted into mouse models. Macromol. Biosci. 11(10), 1364-1369 (2011
141. Arumuganathar S, Irvine S, Mcevan JR, Jayasinghe S. Aerodynamically assisted bio-jets: The development of a novel and direct non-electric field-driven methodology for engineering living organisms. Biomed. Mater. 2, 158-168 (2007
142. Pakes NK, Jayasinghe S, Williams RSB. Bio-electrospraying and aerodynamically assisted bio-jetting the model eukaryotic dictyostelium discoideum: Assessing stress and developmental competency post treatment. J. R. Soc. Interface 8, 1185-1191 (2011
143. Griessinger E, Jayasinghe S, Bonnet D. Aerodynamically assisted bio-jetting of hematopoietic stem cells. Analyst 137, 1329-1333 (2012
144. Linke A, Müller P, Nurzynska D et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc. Natl Acad. Sci. USA 102(25), 8966-8971 (2005
145. Haider HK, Mustafa A, Feng Y, Ashraf M. Genetic modification of stem cells for improved therapy of the infarcted myocardium. Mol. Pharm. 8(5), 1446-1457 (2011
146. Kim SH, Moon HH, Kim HA, Hwang KC, Lee M, Choi D. Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol. Ther. 19(4), 741-750 (2011
147. Cheng Z, Ou L, Zhou X et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther. 16(3), 571-579 (2008